Moximed has announced FDA marketing authorization of its Misha knee system, an implantable shock absorber for patients with knee osteoarthritis, according to a company press release.
The Misha knee system is designed to treat patients with medial knee OA who remain symptomatic after failed operative or nonoperative treatment.
“This is a milestone event for knee OA sufferers, and it’s the result of unwavering clinical research and development that spans more than 10 years,” Anton Clifford, PhD, founder and CEO of Moximed, said in the release. “We’re thrilled to now